GlaxoSmithKline Pharmaceuticals Limited announces results for the full year ended March 31, 2022

Revenue growth at 12%
Dividend of Rs.90 per equity share

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the year ended March 31, 2022. Revenue for the year from Continuing Operations came in at Rs. 3278 crores recording a growth of 12%. PBT (before exceptional) from Continuing Operations for the year at Rs. 767 crores recorded a growth of 22%. EBITDA margin improved by 3%.

Revenue from Continuing Operations for the quarter ended March 31, 2022 was Rs. 810 crores recording a growth of 9%. PBT (before exceptional) from Continuing Operations for the quarter at Rs. 178 crores, recorded a growth of 6%.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "During the year, our General Medicines portfolio continued to gain market share in their respective categories. Our execution focus on key brands helped us revitalise growth particularly in the anti-infectives, dermatology and pain segments.

While our vaccines business was impacted due to low vaccination rates, many of our key brands gained share in a declining market, fuelled by disciplined execution. We continue to maintain market leadership in the private vaccines market.

During the quarter, we concluded the transfer of Iodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited, as part of GSK plc’s plans to create two world class companies in pharmaceuticals and consumer healthcare."

The Board recommended a dividend of Rs. 90 per share which includes a special dividend of Rs. 60 per share.

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contact

Ransom D'Souza
Communications & Government Affairs
Email: ransom.a.dsouza@gsk.com

Back to top